Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
FGEN Stock Chart & Stats
$8.66
>-$0.01(-1.28%)
At close: 4:00 PM EST
$8.66
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$4.85 - $21.94
Previous CloseN/A
Volume937.77K
Average Volume (3M)30.76K
Market Cap
$38.47M
Enterprise Value$133.15M
Total Cash (Recent Filing)$117.97M
Total Debt (Recent Filing)$19.47M
Price to Earnings (P/E)0.2
Beta1.49
Next Earnings
Mar 02, 2026EPS Estimate
-3.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)49.61
Shares Outstanding4,045,445
10 Day Avg. Volume33,010
30 Day Avg. Volume30,760
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-5.87
Price to Sales (P/S)44.72
P/FCF Ratio-9.58
Enterprise Value/Market Cap3.46
Enterprise Value/Revenue-1.13
Enterprise Value/Gross Profit-1.36
Enterprise Value/Ebitda-1.04
Forecast
1Y Price Target
$43.00Price Target Upside396.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash PositionThe company's strong cash position and shrewd utilization of capital has positioned its multiple programs for success.
FG-3246 DevelopmentThe FG-3246 Phase 2 monotherapy trial has been initiated to evaluate its potential in treating mCRPC patients, marking a significant advancement for the program.
Pipeline MilestonesNumerous pipeline milestones are rapidly approaching in 2026, particularly in trials assessing FG-3246.
Bears Say
Cash Runway ConcernAssuming that the company will sponsor the Phase III low-risk MDS study, which is expected to cost $50 million to $60 million, the cash runway will likely be reduced to the second half of 2027 in the absence of additional funding.
Competitive LandscapeThe mCRPC treatment landscape has become increasingly competitive, owing in large part to the commercial success of Pluvicto.
Early Stage ConcernsGiven the early stage of FG-3246, along with the highly competitive prostate cancer market, it is considered prudent to wait for additional data prior to drawing solid conclusions.
FibroGen News
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $4.85 and its highest was $21.94 in the past 12 months.
What is FibroGen’s market cap?
FibroGen’s market cap is $38.47M.
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Mar 02, 2026 which is in 73 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on Nov 10, 2025. The company reported $49.61 earnings per share for the quarter, beating the consensus estimate of -$4.007 by $53.617.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -3.89.
How many shares outstanding does FibroGen have?
FibroGen has 4,045,445 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of $49.61 in its last earnings report, beating expectations of -$4.007. Following the earnings report the stock price went down -9.636%.
Which hedge fund is a major shareholder of FibroGen?
Currently, no hedge funds are holding shares in FGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.00 (396.54% Upside)
$43.00 (396.54% Upside)
Hedge Fund Trend
Decreased
By 30.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $33.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.27%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FGEN Company Deck
FGEN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant achievements, including the transformative sale of FibroGen China, progress in prostate cancer treatment, and successful regulatory engagement for roxadustat. However, these are balanced by the low revenue and net loss figures, along with financial concerns regarding upcoming trials.View all FGEN earnings summariesFGEN Stock 12 Month Forecast
Average Price Target
$43.00
▲(396.54% Upside)
Technical Analysis
Grace Therapeutics
―
Generation Bio
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―
Ownership Overview
10.61% Insiders
23.76% Mutual Funds
11.09% Other Institutional Investors
50.67% Public Companies and
Individual Investors